Testosterone supplementation did not show consistent benefit for cardiovascular risk , sexual function , mood and behavior , or cognition .
Studies that examined clinical cardiovascular endpoints have not favored testosterone therapy over placebo .
Testosterone is ineffective in treating erectile dysfunction and controlled trials did not show a consistent effect on libido .
Testosterone supplementation consistently increased muscle strength but did not have beneficial effects on physical function .
Most studies on mood-related endpoints found no beneficial effect of testosterone treatment on personality , psychological well-being , or mood .
Testosterone products are recommended by some prescribers in response to a diagnosis or presumption of " low testosterone " ( low-T ) for cardiovascular health , sexual function , muscle weakness or wasting , mood and behavior , and cognition .
Androgens and sexual function: a placebo-controlled, randomized, double-blind study of testosterone vs. dehydroepiandrosterone in men with sexual dysfunction and androgen deficiency
Purpose . Supplemental administration of and rogens has been advocated for men with sexual dysfunction ( SD ) and hypo and rogenism . The preponderance of evidence indicates that most delivery forms of testosterone ( T ) are effective but the role of dehydroepi and rosterone ( DHEA ) is controversial . A placebo-controlled , r and omized trial of oral and rogen ( T versus DHEA ) supplementation was carried out to determine their efficacy . Material s and methods . Eighty-six men with SD and decreased levels of serum T and /or DHEA , participated in a study receiving oral T undecanoate ( OTU ) ( n = 29 ) 80 mg twice daily , DHEA ( n = 28 ) 50 mg twice daily , or placebo ( n = 29 ) . Outcomes included evaluation of sexual performance by the International Index of Erectile Function ( IIEF ) , the And rogen Deficiency in the Aging Male ( ADAM ) , Aging Male Symtom Scale ( AMS ) , and Global Assessment Question naire ( GAQ ) question naires . Biochemical evaluations included measurement of T and DHEA , prolactin , gonadotropins , and PSA . Results . Seventy-nine men completed the study . There were no significant differences in outcomes as assessed by four different instruments : the ADAM , IIEF , AMS , and GAQ in regard to sexual interest or erectile function . Biochemically , a significant increase in serum DHEA between baseline and final visit was documented in the group receiving DHEA . The levels of T , on the other h and , increased insignificantly between entry and final visit in the T cohort . No biochemical changes were observed in the placebo group . Levels of PSA remained stable in all three groups . Conclusions . This study did not suggest a clinical benefit of OTU or DHEA supplementation in men with hypo and rogenism and SD . The recommended dose of OTU may have been inadequate or poorly absorbed . Increased doses or an alternative T delivery form may result in a different response
Testosterone supplementation did not show consistent benefit for cardiovascular risk , sexual function , mood and behavior , or cognition .
Studies that examined clinical cardiovascular endpoints have not favored testosterone therapy over placebo .
Testosterone is ineffective in treating erectile dysfunction and controlled trials did not show a consistent effect on libido .
Testosterone supplementation consistently increased muscle strength but did not have beneficial effects on physical function .
Most studies on mood-related endpoints found no beneficial effect of testosterone treatment on personality , psychological well-being , or mood .
Testosterone products are recommended by some prescribers in response to a diagnosis or presumption of " low testosterone " ( low-T ) for cardiovascular health , sexual function , muscle weakness or wasting , mood and behavior , and cognition .